A citation-based method for searching scientific literature

Steven G Chrysant, George S Chrysant. Expert Opin Drug Saf 2020
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Genetics of NO Deficiency.
Kirsten Leineweber, Sven Moosmang, Dan Paulson. Am J Cardiol 2017
4
100


Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.
Robrecht Thoonen, Patrick Y Sips, Kenneth D Bloch, Emmanuel S Buys. Curr Hypertens Rep 2013
28
100


Structure and regulation of soluble guanylate cyclase.
Emily R Derbyshire, Michael A Marletta. Annu Rev Biochem 2012
258
100

Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension.
Mitsushige Murata, Takashi Kawakami, Masaharu Kataoka, Hidenori Moriyama, Takahiro Hiraide, Mai Kimura, Jin Endo, Takashi Kohno, Yuji Itabashi, Keiichi Fukuda. Cardiology 2021
1
100

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Burkert Pieske, Aldo P Maggioni, Carolyn S P Lam, Elisabeth Pieske-Kraigher, Gerasimos Filippatos, Javed Butler, Piotr Ponikowski, Sanjiv J Shah, Scott D Solomon, Andrea-Viviana Scalise,[...]. Eur Heart J 2017
157
100

REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival.
Raymond L Benza, Harrison W Farber, Adaani Frost, Hossein-Ardeschir Ghofrani, Miguel A Gómez-Sánchez, David Langleben, Stephan Rosenkranz, Dennis Busse, Christian Meier, Sylvia Nikkho,[...]. J Heart Lung Transplant 2018
18
100

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Hossein-Ardeschir Ghofrani, Miguel-Angel Gomez Sanchez, Marc Humbert, David Pittrow, Gérald Simonneau, Henning Gall, Ekkehard Grünig, Hans Klose, Michael Halank, David Langleben,[...]. Respir Med 2021
3
100

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Markus Follmann, Jens Ackerstaff, Gorden Redlich, Frank Wunder, Dieter Lang, Armin Kern, Peter Fey, Nils Griebenow, Walter Kroh, Eva-Maria Becker-Pelster,[...]. J Med Chem 2017
49
100

Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
Waqas Ullah, Maryam Mukhtar, Aws Al-Mukhtar, Rehan Saeed, Margot Boigon, Donald Haas, Eduardo Rame. World J Cardiol 2020
3
100

Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.
Sandra Geschka, Axel Kretschmer, Yuliya Sharkovska, Oleg V Evgenov, Bettina Lawrenz, Andreas Hucke, Berthold Hocher, Johannes-Peter Stasch. PLoS One 2011
73
100


Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.
Soundos Saleh, Reiner Frey, Corina Becker, Sigrun Unger, Georg Wensing, Wolfgang Mück. Pulm Circ 2016
7
100

An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
John P Hanrahan, Jelena P Seferovic, James D Wakefield, Phebe J Wilson, Jennifer G Chickering, Joon Jung, Kenneth E Carlson, Daniel P Zimmer, Andrew L Frelinger, Alan D Michelson,[...]. Diabetologia 2020
8
100

Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
Courtney M Shea, Gavrielle M Price, Guang Liu, Renee Sarno, Emmanuel S Buys, Mark G Currie, Jaime L Masferrer. Am J Physiol Renal Physiol 2020
11
100

Nitric Oxide-cGMP Signaling in Hypertension: Current and Future Options for Pharmacotherapy.
Ehsan Ataei Ataabadi, Keivan Golshiri, Annika Jüttner, Guido Krenning, A H Jan Danser, Anton J M Roks. Hypertension 2020
5
100

Emerging Drug Classes and Their Potential Use in Hypertension.
Michel Azizi, Patrick Rossignol, Jean-Sébastien Hulot. Hypertension 2019
19
100


Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling.
Connor A Emdin, Amit V Khera, Derek Klarin, Pradeep Natarajan, Seyedeh M Zekavat, Akihiro Nomura, Mary Haas, Krishna Aragam, Diego Ardissino, James G Wilson,[...]. Circulation 2018
41
100

A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
John P Hanrahan, James D Wakefield, Phebe J Wilson, Marina Mihova, Jennifer G Chickering, Dennis Ruff, Michael Hall, G Todd Milne, Mark G Currie, Albert T Profy. Clin Pharmacol Drug Dev 2019
14
100


Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
Jenny V Tobin, Daniel P Zimmer, Courtney Shea, Peter Germano, Sylvie G Bernier, Guang Liu, Kim Long, Joy Miyashiro, Sheila Ranganath, Sarah Jacobson,[...]. J Pharmacol Exp Ther 2018
27
100

Medication Adherence and Incident Preventable Hospitalizations for Hypertension.
Julie C Will, Zefeng Zhang, Matthew D Ritchey, Fleetwood Loustalot. Am J Prev Med 2016
15
100

Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.
Linda Brockunier, John Stelmach, Jian Guo, Tracy Spencer, Keith Rosauer, Alka Bansal, Sheng-Jian Cai, Nancy Chen, John Cummings, Li Huang,[...]. Bioorg Med Chem Lett 2020
1
100


Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
Michael Boettcher, Dirk Thomas, Wolfgang Mueck, Stephanie Loewen, Erich Arens, Kenichi Yoshikawa, Corina Becker. Eur J Clin Pharmacol 2021
5
100

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
Mihai Gheorghiade, Stephen J Greene, Gerasimos Filippatos, Erland Erdmann, Roberto Ferrari, Phillip D Levy, Aldo Maggioni, Christina Nowack, Alexandre Mebazaa. Eur J Heart Fail 2012
77
100

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Mihai Gheorghiade, Stephen J Greene, Javed Butler, Gerasimos Filippatos, Carolyn S P Lam, Aldo P Maggioni, Piotr Ponikowski, Sanjiv J Shah, Scott D Solomon, Elisabeth Kraigher-Krainer,[...]. JAMA 2015
157
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.